ConductScience.org, home

Paper50294

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity.

Herberman RB and 2 others. Int J Cancer, 1975. Cited by 1,354 papers, by iCite.

Cite this record

ConductScience Library. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Papers, record 50294. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/50294

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity.
PubMed
Journal
Int J Cancer
PubMed
Year
1975
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1,354
iCite
Relative citation ratio, by iCite
25.1
iCite
Revised in PubMed
2019-07-08
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Herberman RBR B
2Nunn MEM E
3Lavrin DHD H

Source PubMed

Download CSV of authors

Topics26

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunity, CellularMajor topic
LymphocytesMajor topic
Lymphoid TissueMajor topic
Neoplasms, ExperimentalMajor topic
Age Factors
Animals
Ascitic Fluid
Cell Line
Cytotoxicity Tests, Immunologic
Epitopes
Female
Lymph Nodes
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C3H
Mice, Inbred C57BL
Mice, Inbred CBA
Mice, Inbred NZB
Mice, Nude
Neoplasm Transplantation
Retroviridae
Sarcoma Viruses, Murine
Spleen
Transplantation, Homologous
Transplantation, Isogeneic

Source PubMed

Download CSV of topics

Cited by404

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,354 citations.

PMIDTitleJournalYearIn PapersSource
42926223CAR-NK cell immunotherapy: a comprehensive review of engineering platforms, clinical applications in hematological and solid tumors.J Cancer Res Clin Oncol2026https://conductscience.org/library/papers/42926223PubMed
42904056Cytomics-driven insights for investigating host-pathogen interactions.Hlife2026https://conductscience.org/library/papers/42904056PubMed
42881185Next-generation natural killer cell therapy: bench to bedside and beyond.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42881185PubMed
42769371Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases.MedComm (2020)2026https://conductscience.org/library/papers/42769371PubMed
42046345Tumor microenvironment-driven natural killer cell diversity: mechanisms and therapeutic opportunities.Cancer Biol Med2026https://conductscience.org/library/papers/42046345PubMed
41986797PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGFβ1 responses.EMBO Rep2026https://conductscience.org/library/papers/41986797PubMed
41512874Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy.Cell Stem Cell2026https://conductscience.org/library/papers/41512874PubMed
41331607MicroRNA-mediated regulation of natural killer cells development, effector functions, and antitumor responses.Cancer Cell Int2025https://conductscience.org/library/papers/41331607PubMed
41280924Precision medicine with car cells in acute myeloid leukemia: where are we?Front Immunol2025https://conductscience.org/library/papers/41280924PubMed
41188903Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.J Transl Med2025https://conductscience.org/library/papers/41188903PubMed
41107895The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies.Cancer Cell Int2025https://conductscience.org/library/papers/41107895PubMed
40728766Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses.J Clin Immunol2025https://conductscience.org/library/papers/40728766PubMed
40246292Natural killer cell-based immunotherapy for cancer.J Immunol2025https://conductscience.org/library/papers/40246292PubMed
40211394Natural killer cells: the immune frontline against circulating tumor cells.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40211394PubMed
40149002The clinical landscape of CAR NK cells.Exp Hematol Oncol2025https://conductscience.org/library/papers/40149002PubMed
39906666MiR-216a-3p inhibits the cytotoxicity of primary natural killer cells.Front Oncol2024https://conductscience.org/library/papers/39906666PubMed
39754720Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells.Cell Rep2025https://conductscience.org/library/papers/39754720PubMed
39511139Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39511139PubMed
39395921Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury.Arch Toxicol2025https://conductscience.org/library/papers/39395921PubMed
39362494N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial.Transplant Cell Ther2024https://conductscience.org/library/papers/39362494PubMed

See all 404 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/50294

GET https://conductscience.org/api/papers/v1/50294/cited_by?page=2